IL-28B/IFN-lambda 3 Antibodies

HAF007). A specific band was detected for IL-28B/IFN-lambda 3 at approximately 19 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_lightbox"> HAF007). A specific band was detected for IL-28B/IFN-lambda 3 at approximately 19 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." alt="Western blot shows lysates of human monocytes treated (+) with 10 ng/mL of rhIFN-alpha for 24 hours and then further stimulated with 10 µg/mL of poly I:C for 48 hours. PVDF Membrane was probed with 2 µg/mL of Mouse Anti-Human IL-28B/IFN-lambda 3 Monoclonal Antibody (Catalog # MAB5259) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for IL-28B/IFN-lambda 3 at approximately 19 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />

1789-ML) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Mouse IL-28B/ IFN-lambda 3 (400 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse IL-28B/IFN-lambda 3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1789). The ND₅₀ is typically 2-10 µg/mL." class="big_lightbox"> 1789-ML) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Mouse IL-28B/ IFN-lambda 3 (400 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse IL-28B/IFN-lambda 3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1789). The ND₅₀ is typically 2-10 µg/mL." alt="Recombinant Mouse IL-28B/IFN-lambda 3 (Catalog # 1789-ML) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Mouse IL-28B/ IFN-lambda 3 (400 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse IL-28B/IFN-lambda 3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1789). The ND₅₀ is typically 2-10 µg/mL." class="big_thumb" />

1789-ML) reduces the Encephalo-myocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Mouse IL-28B/IFN-lambda 3 (400 ng/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse IL-28B/IFN-lambda 3 Monoclonal Antibody (Cata-log # MAB1789). The ND₅₀ is typically 1.5-6.0 µg/mL." class="big_lightbox"> 1789-ML) reduces the Encephalo-myocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Mouse IL-28B/IFN-lambda 3 (400 ng/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse IL-28B/IFN-lambda 3 Monoclonal Antibody (Cata-log # MAB1789). The ND₅₀ is typically 1.5-6.0 µg/mL." alt="Recombinant Mouse IL-28B/ IFN-lambda 3 (Catalog # 1789-ML) reduces the Encephalo-myocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Mouse IL-28B/IFN-lambda 3 (400 ng/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse IL-28B/IFN-lambda 3 Monoclonal Antibody (Cata-log # MAB1789). The ND₅₀ is typically 1.5-6.0 µg/mL." class="big_thumb" />